Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rth2.12064 http://scihub22266oqcxt.onion/10.1002/rth2.12064 C5974913!5974913!30046704     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Res+Pract+Thromb+Haemost 2018 ; 2 (1): 34-41 Nephropedia Template TP {{tp|p=30046704|t=2018. Current issues in diagnosis and treatment of von Willebrand disease |pdf=|usr=}}{{30046704}} gab.com Text Current issues in diagnosis and treatment of von Willebrand disease JO: Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=30046704 #FOAvip Essentials: Classification of VWD includes quantitative (types 1 and 3) and qualitative (type 2) variants.New assays of VWF?platelet binding may improve accuracy in diagnosis.Collagen binding represents an additional function of VWF not measured by current tests.Treatment options for VWD include desmopressin, plasma?derived, and recombinant VWF.Clinically, von Willebrand disease (VWD) presents as mucosal bleeding caused by a decreased quantity or quality of von Willebrand factor (VWF). Diagnosis of VWD requires careful consideration of patient specific factors, bleeding symptoms, and laboratory results. Patients with borderline low VWF levels remain challenging, given that low VWF is not necessarily a guarantee of bleeding, but is present in many patients with symptoms, and treatment of low VWF may improve bleeding. Laboratory diagnosis of VWD is complex and no single test can determine the presence or absence of functional VWF. Historically, VWF binding to platelet GPIb? was measured by the ristocetin cofactor assay (VWF:RCo); a new assay using platelet GPIb? in the absence of ristocetin (VWF:GPIbM) is gradually replacing the VWF:RCo due to improved accuracy in diagnosis. VWF binding to collagen is a separate function, and requires specific testing to determine if a collagen binding defect is present. Regardless of these laboratory complexities, clinicians can empirically treat VWD to alleviate bleeding symptoms by raising VWF levels through desmopressin or VWF concentrate. Recombinant VWF is now available, but clinicians may need to add an initial dose of FVIII when treating emergency bleeds. Twit Text FOAVip Current issues in diagnosis and treatment of von Willebrand disease ????Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=30046704 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30046704 #FOAvip English Wikipedia <ref>{{Cite pmid|30046704}}</ref> Current issues in diagnosis and treatment of von Willebrand disease #MMPMID30046704 Keesler DA; Flood VH Res Pract Thromb Haemost 2018[Jan]; 2 (1): 34-41 PMID30046704show ga Essentials: Classification of VWD includes quantitative (types 1 and 3) and qualitative (type 2) variants.New assays of VWF?platelet binding may improve accuracy in diagnosis.Collagen binding represents an additional function of VWF not measured by current tests.Treatment options for VWD include desmopressin, plasma?derived, and recombinant VWF.Clinically, von Willebrand disease (VWD) presents as mucosal bleeding caused by a decreased quantity or quality of von Willebrand factor (VWF). Diagnosis of VWD requires careful consideration of patient specific factors, bleeding symptoms, and laboratory results. Patients with borderline low VWF levels remain challenging, given that low VWF is not necessarily a guarantee of bleeding, but is present in many patients with symptoms, and treatment of low VWF may improve bleeding. Laboratory diagnosis of VWD is complex and no single test can determine the presence or absence of functional VWF. Historically, VWF binding to platelet GPIb? was measured by the ristocetin cofactor assay (VWF:RCo); a new assay using platelet GPIb? in the absence of ristocetin (VWF:GPIbM) is gradually replacing the VWF:RCo due to improved accuracy in diagnosis. VWF binding to collagen is a separate function, and requires specific testing to determine if a collagen binding defect is present. Regardless of these laboratory complexities, clinicians can empirically treat VWD to alleviate bleeding symptoms by raising VWF levels through desmopressin or VWF concentrate. Recombinant VWF is now available, but clinicians may need to add an initial dose of FVIII when treating emergency bleeds. äCurrent issues in diagnosis and treatment of von Willebrand disease (epmc).pdf DeepDyve Pubget Overpricing